ELITechGroup Molecular Diagnostics distributes 3.5 million SARS-CoV-2 tests
ELITechGroup Molecular Diagnostics, a leading global provider of diagnostic testing products, passed a significant milestone early August with the distribution of more than 3.5 million SARS-CoV-2 tests worldwide. The company has also installed more than 500 of its lead diagnostics instrument, the ELITe InGenius polymerase chain reaction (PCR) system, globally, with over a hundred placed since the beginning of the pandemic. The system allows laboratories to reliably detect SARS-CoV2 in only a few hours, as well as conducting parallel testing for other diseases, such as flu, in order to ensure a correct diagnosis.
The ELITe InGenius has been widely used in hospitals and other healthcare settings since 2016, and ELITechGroup was among the first companies to have SARS-CoV-2 tests on a sample-to-result system.
The ELITe InGenius is a fully automated solution that can process 12 samples in parallel to deliver results in less than 2.5 hours. This brings several benefits over centralized high-throughput testing approaches as there is no waiting for a large batch of samples to accumulate before testing, and no delays from sending samples off premises to a central laboratory.
By performing extraction, amplification and result interpretation in one device, the ELITe InGenius replaces the multiple devices needed to perform such tasks separately. Full automation also means there is no need for constant supervision, allowing laboratory staff to perform other valuable work. More importantly, the limited hands-on time helps reduce the risk of infection for users. The instrument is straightforward to use, with only minimal training required from ELITechGroup’s service and support team.
The ELITe InGenius offers the widest molecular diagnostics menu available on a sample-to-result system, with 38 CE-IVD assays dedicated to the unique needs of healthcare settings, be it immunocompromised patient monitoring; detection of respiratory, gastro-intestinal, sexually transmitted or nosocomial infections; meningitis and encephalitis, as well as diagnostics of genetic factors.
Commenting on the advantages of the ELITe InGenius for hospital settings, Dr Anna Paola Callegaro, Virology Area Coordinator and Biobank UOSD Director of ASST Papa Giovanni XXIII – Bergamo (Italy), commented: “The modular configuration of the ELITe InGenius system enables us to carry out molecular virology routine with results on the day. The sample-to-result solution reduces the need for manual intervention by the technician and allows the analysis of multiple viral targets on the same sample, thereby significantly improving the lab’s efficiency.”
Christoph Gaue, ELITechGroup CEO, said the company has expanded their manufacturing capacity to help provide additional ELITe InGenius systems to hospitals and laboratories, globally.
For more information, visit: www.elitechgroup.com